$1.02 Million in Sales Expected for Abeona Therapeutics Inc (ABEO) This Quarter

Wall Street brokerages expect that Abeona Therapeutics Inc (NASDAQ:ABEO) will report sales of $1.02 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Abeona Therapeutics’ earnings, with the lowest sales estimate coming in at $200,000.00 and the highest estimate coming in at $1.81 million. Abeona Therapeutics posted sales of $220,000.00 during the same quarter last year, which suggests a positive year-over-year growth rate of 363.6%. The company is expected to issue its next quarterly earnings report on Wednesday, November 21st.

On average, analysts expect that Abeona Therapeutics will report full-year sales of $6.08 million for the current fiscal year, with estimates ranging from $5.63 million to $6.83 million. For the next year, analysts forecast that the company will post sales of $18.32 million, with estimates ranging from $4.23 million to $43.30 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Abeona Therapeutics.

Abeona Therapeutics (NASDAQ:ABEO) last announced its earnings results on Friday, August 10th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.06). Abeona Therapeutics had a negative net margin of 881.74% and a negative return on equity of 23.02%. The firm had revenue of $0.82 million during the quarter, compared to analyst estimates of $1.81 million.

ABEO has been the subject of several analyst reports. Zacks Investment Research raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 24th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Abeona Therapeutics in a research note on Thursday, September 13th. Cantor Fitzgerald set a $36.00 price objective on shares of Abeona Therapeutics and gave the company a “buy” rating in a research note on Monday, October 1st. TheStreet downgraded shares of Abeona Therapeutics from a “c-” rating to a “d+” rating in a research note on Wednesday, August 29th. Finally, ValuEngine downgraded shares of Abeona Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 30th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $26.80.

Several hedge funds and other institutional investors have recently bought and sold shares of ABEO. FMR LLC increased its stake in shares of Abeona Therapeutics by 47.7% during the 2nd quarter. FMR LLC now owns 7,094,307 shares of the biopharmaceutical company’s stock valued at $113,509,000 after acquiring an additional 2,291,016 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Abeona Therapeutics by 2,357.3% during the 1st quarter. Millennium Management LLC now owns 916,256 shares of the biopharmaceutical company’s stock worth $13,148,000 after purchasing an additional 878,969 shares during the period. PointState Capital LP purchased a new stake in shares of Abeona Therapeutics during the 2nd quarter worth about $9,210,000. Nexthera Capital LP purchased a new stake in shares of Abeona Therapeutics during the 1st quarter worth about $5,302,000. Finally, BlackRock Inc. grew its holdings in shares of Abeona Therapeutics by 16.6% during the 2nd quarter. BlackRock Inc. now owns 2,184,506 shares of the biopharmaceutical company’s stock worth $34,951,000 after purchasing an additional 311,034 shares during the period. 76.24% of the stock is owned by institutional investors.

ABEO stock traded up $0.37 during trading on Wednesday, hitting $10.40. The stock had a trading volume of 629,959 shares, compared to its average volume of 886,407. Abeona Therapeutics has a 1-year low of $9.66 and a 1-year high of $22.00. The company has a market capitalization of $613.67 million, a price-to-earnings ratio of -15.76 and a beta of 1.10.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Further Reading: Using the New Google Finance Tool

Get a free copy of the Zacks research report on Abeona Therapeutics (ABEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply